AMNESTROGEN Drug Patent Profile
✉ Email this page to a colleague
When do Amnestrogen patents expire, and when can generic versions of Amnestrogen launch?
Amnestrogen is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in AMNESTROGEN is estrogens, esterified. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, esterified profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMNESTROGEN?
- What are the global sales for AMNESTROGEN?
- What is Average Wholesale Price for AMNESTROGEN?
Summary for AMNESTROGEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| DailyMed Link: | AMNESTROGEN at DailyMed |
US Patents and Regulatory Information for AMNESTROGEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | AMNESTROGEN | estrogens, esterified | TABLET;ORAL | 083266-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | AMNESTROGEN | estrogens, esterified | TABLET;ORAL | 083266-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | AMNESTROGEN | estrogens, esterified | TABLET;ORAL | 083266-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | AMNESTROGEN | estrogens, esterified | TABLET;ORAL | 083266-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
